ZIXXIVUS Trademark

Trademark Overview


On Friday, August 18, 2023, a trademark application was filed for ZIXXIVUS with the United States Patent and Trademark Office. The USPTO has given the ZIXXIVUS trademark a serial number of 98139376. The federal status of this trademark filing is SECOND EXTENSION - GRANTED as of Friday, January 3, 2025. This trademark is owned by Vanda Pharmaceuticals Inc.. The ZIXXIVUS trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; Pharmaceutical preparations for the central nervous system; Pharmaceutical preparations for the prevention of motion sickness; Pharmaceutical preparations for the prevention of social anxiety or performance anxiety; Pharmaceutical preparations for the treatment and prevention of craving; Pharmaceutical preparations for the treatment and prevention of motion sickness; Pharmaceutical preparations for the treatment and prevention of insomnia; Pharmaceutical preparations for the treatment and prevention of social anxiety or performance anxiety; Pharmaceutical preparations for the treatment of circadian rhythm diseases and disorders; Pharmaceutical preparations for the treatment of Non-24-Hour Sleep-Wake Disorder; Pharmaceutical preparat...
zixxivus

General Information


Serial Number98139376
Word MarkZIXXIVUS
Filing DateFriday, August 18, 2023
Status731 - SECOND EXTENSION - GRANTED
Status DateFriday, January 3, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 19, 2023

Trademark Statements


Goods and ServicesPharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; Pharmaceutical preparations for the central nervous system; Pharmaceutical preparations for the prevention of motion sickness; Pharmaceutical preparations for the prevention of social anxiety or performance anxiety; Pharmaceutical preparations for the treatment and prevention of craving; Pharmaceutical preparations for the treatment and prevention of motion sickness; Pharmaceutical preparations for the treatment and prevention of insomnia; Pharmaceutical preparations for the treatment and prevention of social anxiety or performance anxiety; Pharmaceutical preparations for the treatment of circadian rhythm diseases and disorders; Pharmaceutical preparations for the treatment of Non-24-Hour Sleep-Wake Disorder; Pharmaceutical preparations for the treatment of jet lag disorder; Pharmaceutical preparations for the treatment of Delayed Sleep Phase Disorder (DSPD); Pharmaceutical preparations for the treatment of bipolar disorder; Pharmaceutical preparations for the treatment of schizophrenia; Pharmaceutical preparations for the treatment of atopic dermatitis; Pharmaceutical preparations for the treatment of pruritus; Pharmaceutical preparations for the treatment of gastroparesis; Pharmaceutical preparations for the treatment of motion sickness; Pharmaceutical preparations for the treatment of hematologic malignancies; Pharmaceutical preparations for the treatment of insomnia; Pharmaceutical preparations for the treatment of Autism Spectrum Disorder (ASD); Pharmaceutical preparations for the treatment of Parkinson's Disease Psychosis; Pharmaceutical preparations for the treatment of COVID-19 pneumonia; Pharmaceutical preparations for the treatment of social anxiety or performance anxiety; Pharmaceutical preparations for the treatment of Smith-Magenis Syndrome; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for use in dermatology

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, September 18, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameVanda Pharmaceuticals Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressWashington, DC 20037

Party NameVanda Pharmaceuticals Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressWashington, DC 20037

Trademark Events


Event DateEvent Description
Tuesday, August 22, 2023NEW APPLICATION ENTERED
Thursday, November 16, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, September 18, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, November 13, 2023ASSIGNED TO EXAMINER
Tuesday, December 19, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Wednesday, November 29, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, December 19, 2023PUBLISHED FOR OPPOSITION
Tuesday, February 13, 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Monday, June 17, 2024SOU TEAS EXTENSION RECEIVED
Monday, June 17, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, June 17, 2024SOU EXTENSION 1 FILED
Monday, June 17, 2024SOU EXTENSION 1 GRANTED
Thursday, January 2, 2025SOU TEAS EXTENSION RECEIVED
Friday, January 3, 2025SOU EXTENSION 2 FILED
Friday, January 3, 2025SOU EXTENSION 2 GRANTED
Tuesday, March 4, 2025NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED